<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Microbiol Infect</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Microbiol. Infect</journal-id><journal-title-group><journal-title>Clinical Microbiology and Infection</journal-title></journal-title-group><issn pub-type="ppub">1198-743X</issn><issn pub-type="epub">1469-0691</issn><publisher><publisher-name>European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7434691</article-id><article-id pub-id-type="publisher-id">S1198-743X(20)30494-8</article-id><article-id pub-id-type="doi">10.1016/j.cmi.2020.08.012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Coinfection with other respiratory pathogens in COVID-19 patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Calcagno</surname><given-names>Andrea</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Ghisetti</surname><given-names>Valeria</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Burdino</surname><given-names>Elisa</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Trunfio</surname><given-names>Mattia</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Allice</surname><given-names>Tiziano</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Boglione</surname><given-names>Lucio</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Bonora</surname><given-names>Stefano</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Di Perri</surname><given-names>Giovanni</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1)</label>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Italy</aff><aff id="aff2"><label>2)</label>Laboratory of Microbiology and Virology, Ospedale Amedeo di Savoia, ASL &#x02018;Citt&#x000e0; di Torino&#x02019;, Torino, Italy</aff><aff id="aff3"><label>3)</label>University of Eastern Piedmont, Department of Translational Medicine, Novara, Italy</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Valeria Ghisetti, Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, C.so Svizzera 164, 10149 Torino, Italy.</corresp><fn id="fn1"><label>&#x02020;</label><p id="ntpara0010">The first two authors contributed equally to this letter, and both should be considered first author.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>19</day><month>8</month><year>2020</year></pub-date><history><date date-type="received"><day>20</day><month>6</month><year>2020</year></date><date date-type="rev-recd"><day>8</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>European Society of Clinical Microbiology and Infectious Diseases</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta><notes><p id="misc0010">Editor: L. Leibovici</p></notes></front><body><p id="p0010">As a result of the clinical similarity of coronavirus disease 2019 (COVID-19) with other flulike syndromes, patients were tested for other pathogens of respiratory tract infections as well, especially in the first weeks of the epidemic. In those weeks, we used the multiplex PCR BioFire FilmArray Pneumonia panel (BioFire Diagnostics; bioM&#x000e9;rieux, Marcy l&#x02019;&#x000c9;toile, France), allowing the detection of 33 respiratory pathogens with a run time of 1&#x000a0;hour. Here we report the aetiologic pattern of respiratory tract infections diagnosed at the Amedeo di Savoia Hospital, the regional reference centre for infectious diseases of Piedmont, north-western Italy, during the first weeks of the COVID-19 epidemic.</p><p id="p0015">We retrospectively reviewed clinical and microbiologic records generated via routine clinical practice (ethical approval not required) from 162 consecutive patients (93 male; median age, 64&#x000a0;years; range, 12&#x02013;93&#x000a0;years) from 12 February to 31 March 2020 with respiratory symptoms who were screened with FilmArray and real-time reverse transcriptase PCR for COVID-19 diagnosis after multiple sample collection in Copan UTM transport medium (Copan, Brescia, Italy). For the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific RNA, a multiplex Real Time PCR Kit (Liferiver, San Diego, CA, USA) was used (detection limit, 1&#x000a0;&#x000d7;&#x000a0;10&#x000b3; copies/mL). The kit measures three virus genes simultaneously: SARS-CoV-2 gene E, N and ORF1ab. The ABI Prism 7500 thermal cycler was used for PCR amplification (Thermo Fisher Scientific, Waltham, MA, USA) [<xref rid="bib1" ref-type="bibr">1</xref>]. The results of the two tests were compared by the chi-square test.</p><p id="p0020">We included nasopharyngeal swab (123/162, 75.9%), bronchoalveolar lavage (17/162, 10.5%), bronchoaspirate (12/162, 7.4%) and sputum (10/162, 6.2%) samples. SARS-CoV-2 RNA was detected in 56 (34.6%) of 162 samples, while FilmArray showed the presence of viruses and/or bacteria in 63 (38.9%) of 162. FilmArray results (28 samples with multiple microorganisms) identified bacteria in 53 (84.1%) of 63 patients and viruses in 22 (34.9%) of 63, as follows: Staphylococcus aureus (25/63, 39.7%), Haemophilus influenzae (15/63, 23.8%), group B streptococci (6/63, 9.5%), influenza A virus (5/63, 7.9%) and influenza B, coronaviruses and rhinoviruses/enteroviruses (each 4/63, 6.3%).</p><p id="p0025">FilmArray results were positive in 10 of 56 SARS-CoV-2&#x02013;infected patients (17.8% vs. 50% in SARS-CoV-2&#x02013;negative samples, &#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;15.9, p &#x0003c;0.001); interestingly, no other virus was found in SARS-CoV-2&#x02013;positive patients (0 vs. 20.7%, &#x003c7;<sup>2</sup>&#x000a0;=&#x000a0;13.4, p &#x0003c;0.001), but only Staphylococcus aureus (7/10), Haemophilus influenzae (2/10), Escherichia coli (2/10), Moraxella catarrhalis, group B streptococci, Klebsiella pneumoniae and Enterobacter cloacae (1/10 each), most probably as a result of colonization or bacterial superinfection in two COVID-19 patients whose bronchoaspirate tested positive for Haemophilus influenzae plus Escherichia coli and Staphylococcus aureus, respectively (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>
). Soon after the onset of the global SARS-CoV-2 epidemic, the presence of other respiratory viruses declined and even disappeared (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>
).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Positive FilmArray results for respiratory tract microbiologic characterization in patients according to SARS-CoV-2 infection test result</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>FilmArray POSITIVE SARS-COV-2 NEGATIVE</th><th>FilmArray POSITIVE SARS-COV-2 POSITIVE</th></tr></thead><tbody><tr><td>No. of patients</td><td>53</td><td>10</td></tr><tr><td>Age (years) (&#x000b1;SD)</td><td>62.4 &#x000b1; 18</td><td>63.3 &#x000b1; 18</td></tr><tr><td>Sex (F/M)</td><td>25/28</td><td>4/6</td></tr><tr><td>No. of nasopharyngeal swabs</td><td>40</td><td>8</td></tr><tr><td>No. of other type of specimens</td><td>13<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td>2<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td></tr><tr><td colspan="3">No. of pathogens detected</td></tr><tr><td>&#x000a0;<italic>Staphylococcus aureus</italic></td><td>18</td><td>7</td></tr><tr><td>&#x000a0;<italic>Moraxella catarrhalis</italic></td><td>7</td><td>1</td></tr><tr><td>&#x000a0;Haemophilus influenzae</td><td>13</td><td>2</td></tr><tr><td>&#x000a0;<italic>Streptococcus agalactiae</italic></td><td>5</td><td>1</td></tr><tr><td>&#x000a0;<italic>Mycoplasma pneumoniae</italic></td><td>4</td><td>&#x02014;</td></tr><tr><td>&#x000a0;<italic>Streptococcus pneumoniae</italic></td><td>3</td><td>&#x02014;</td></tr><tr><td>&#x000a0;<italic>Streptococcus pyogenes</italic></td><td>3</td><td>&#x02014;</td></tr><tr><td>&#x000a0;<italic>Pseudomonas aeruginosa</italic></td><td>2</td><td>&#x02014;</td></tr><tr><td>&#x000a0;<italic>Enterobacter cloacae</italic></td><td>3</td><td>1</td></tr><tr><td>&#x000a0;<italic>Klebsiella oxytoca</italic></td><td>1</td><td>&#x02014;</td></tr><tr><td>&#x000a0;<italic>Klebsiella pneumoniae</italic></td><td>4</td><td>1</td></tr><tr><td>&#x000a0;<italic>Escherichia coli</italic></td><td>3</td><td>1</td></tr><tr><td>&#x000a0;Adenovirus</td><td>1</td><td>&#x02014;</td></tr><tr><td>&#x000a0;Influenza virus B</td><td>4</td><td>&#x02014;</td></tr><tr><td>&#x000a0;Influenza virus A</td><td>5</td><td>&#x02014;</td></tr><tr><td>&#x000a0;RSV</td><td>2</td><td>&#x02014;</td></tr><tr><td>&#x000a0;Rhinovirus/enterovirus</td><td>4</td><td>&#x02014;</td></tr><tr><td>&#x000a0;Coronavirus (OC43, NL63, 229E)</td><td>4</td><td>&#x02014;</td></tr><tr><td>&#x000a0;Metapneumovirus</td><td>3</td><td>&#x02014;</td></tr><tr><td>Total pathogens</td><td>89</td><td>14</td></tr></tbody></table><table-wrap-foot><fn><p>SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">Sputum (<italic>n</italic> = 6), bronchoalveolar lavage (<italic>n</italic> = 4) and brochoaspirates (<italic>n</italic> = 3).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">Bronchoaspirates (<italic>n</italic> = 2).</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Prevalence of positive samples by date. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></caption><alt-text id="alttext0015">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0030">Our data are consistent with the absence of other respiratory virus coinfection in SARS-CoV-2 patients and a low bacterial coinfection rate mostly reflecting a carriage status.</p><p id="p0035">Recently several articles have reported the possible concomitant presence of respiratory pathogens in subjects with COVID-19. Viral and bacterial pathogens have been described in case reports, case series and four cohorts: a low prevalence was reported (1.6&#x02013;6.5%), with the exception of a single recent report (24/116, 20.7%) [<xref rid="bib2" ref-type="bibr">2</xref>]. Phenomena like viral interference, common receptor usage, different inoculum size or simply resource competition might explain why dual or multiple concurrent viral respiratory infections are rare [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. Few articles have addressed the clinical features of coinfected patients, with the relevant exception of a child with SARS-CoV-2, metapneumovirus and respiratory syncytial virus admitted to an intensive care unit, with no increased risk of severe disease reported [<xref rid="bib5" ref-type="bibr">5</xref>]. In line with this, a 9-year-old child included in the French Alps cluster was coinfected with SARS-CoV-2, rhinovirus/enterovirus and influenza H1N1 and asymptomatic, but no secondary cases were found among his contacts [<xref rid="bib6" ref-type="bibr">6</xref>].</p><p id="p0040">In conclusion, a multiplex PCR system for the rapid diagnosis of respiratory infections revealed that there is virtually no concomitant infection in patients positive for SARS-CoV-2. In addition, interestingly, with the spread of SARS-CoV-2, other respiratory pathogens have seemed to vanish.</p><sec sec-type="supplementary-material" id="sec1"><title>Transparency declaration</title><p id="p0045">AC has received honoraria from AbbVie, BMS, Gilead, Janssen-Cilag, MSD and Viiv and he is currently receiving research grants from BMS, Gilead and Viiv. GDP and SB have received honoraria from AbbVie, BMS, Gilead, Janssen-Cilag, MSD and Viiv. The remaining authors report no conflicts of interest relevant to this letter.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Landt</surname><given-names>O.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Molenkamp</surname><given-names>R.</given-names></name><name><surname>Meijer</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>D.K.W.</given-names></name></person-group><article-title>Detection of 2019 novel coronavirus (2019-nCoV) by realtime RT-PCR</article-title><source>Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull</source><volume>25</volume><year>2020</year><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Quinn</surname><given-names>J.</given-names></name><name><surname>Pinsky</surname><given-names>B.</given-names></name><name><surname>Shah</surname><given-names>N.H.</given-names></name><name><surname>Brown</surname><given-names>I.</given-names></name></person-group><article-title>Rates of coinfection between SARS-CoV-2 and other respiratory pathogens</article-title><source>JAMA</source><year>2020</year><fpage>E1</fpage><lpage>E2</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6266</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Pinky</surname><given-names>L.</given-names></name><name><surname>Dobrovolny</surname><given-names>H.M.</given-names></name></person-group><article-title>Coinfections of the respiratory tract: viral competition for resources</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0155589</pub-id><comment>e0155589</comment></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Goka</surname><given-names>E.A.</given-names></name><name><surname>Vallely</surname><given-names>P.J.</given-names></name><name><surname>Mutton</surname><given-names>K.J.</given-names></name><name><surname>Klapper</surname><given-names>P.E.</given-names></name></person-group><article-title>Single, dual and multiple respiratory virus infections and risk of hospitalization and mortality</article-title><source>Epidemiol Infect</source><volume>143</volume><year>2015</year><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1017/S0950268814000302</pub-id><pub-id pub-id-type="pmid">24568719</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Danis</surname><given-names>K.</given-names></name><name><surname>Epaulard</surname><given-names>O.</given-names></name><name><surname>B&#x000e9;net</surname><given-names>T.</given-names></name><name><surname>Gaymard</surname><given-names>A.</given-names></name><name><surname>Campoy</surname><given-names>S.</given-names></name><name><surname>Bothelo-Nevers</surname><given-names>E.</given-names></name></person-group><article-title>Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, 2020</article-title><source>Clin Infect Dis</source><volume>71</volume><year>2020</year><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa424</pub-id><pub-id pub-id-type="pmid">32277759</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Xiong</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children</article-title><source>Clin Chem Lab Med</source><year>2020</year><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1515/cclm-2020-0434</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0050">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material>
</p></sec><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0055">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cmi.2020.08.012" id="intref0010">https://doi.org/10.1016/j.cmi.2020.08.012</ext-link>.</p></fn></fn-group></back></article>